Publication:

Phase 3 Randomized Study of Daratumumab (DARA) Plus Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned as Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial